Tigermed(300347)

Search documents
医疗服务板块9月24日跌2.01%,南模生物领跌,主力资金净流出3.18亿元
Zheng Xing Xing Ye Ri Bao· 2025-09-24 08:39
Market Overview - On September 24, the medical services sector declined by 2.01%, with Nanmo Biology leading the drop [1] - The Shanghai Composite Index closed at 3853.64, up 0.83%, while the Shenzhen Component Index closed at 13356.14, up 1.8% [1] Individual Stock Performance - Bid Medicine (688073) saw a closing price of 74.63, with a gain of 5.74% and a trading volume of 13,300 hands, totaling a transaction value of 98.38 million [1] - Tiger Medical (300347) closed at 61.00, up 5.54%, with a trading volume of 150,500 hands and a transaction value of 908 million [1] - Guangzheng Eye Hospital (002524) closed at 4.23, up 4.44%, with a trading volume of 189,200 hands and a transaction value of 78.72 million [1] - Nanmo Biology (688265) closed at 52.35, down 1.75%, with a trading volume of 11,300 hands and a transaction value of 59.06 million [2] Capital Flow Analysis - The medical services sector experienced a net outflow of 318 million from institutional investors and 117 million from retail investors, while retail investors saw a net inflow of 434 million [2][3] - Tiger Medical (300347) had a net inflow of 10.8 million from institutional investors but a net outflow of 9.19 million from retail investors [3] - Eye Care (300015) recorded a net inflow of 37.33 million from institutional investors, while retail investors had a net outflow of 41.60 million [3]
泰格医药股价涨5.17%,摩根基金旗下1只基金重仓,持有1.81万股浮盈赚取5.41万元
Xin Lang Cai Jing· 2025-09-24 02:39
Group 1 - The core viewpoint of the news is that Tiger Med has seen a significant increase in its stock price, rising by 5.17% to reach 60.79 CNY per share, with a total market capitalization of 52.342 billion CNY [1] - Tiger Med, established on December 15, 2004, and listed on August 17, 2012, specializes in providing professional clinical research services for pharmaceutical and health-related products, covering a range of services from Phase I to IV clinical trials [1] - The company's main revenue sources include clinical trial-related services and laboratory services, accounting for 52.60%, clinical trial technical services at 45.21%, and other supplementary services at 2.19% [1] Group 2 - Morgan Fund has a significant holding in Tiger Med, with the Morgan CSI Innovative Drug Industry ETF (560900) reducing its stake by 3,000 shares in the second quarter, now holding 18,100 shares, which represents 2.76% of the fund's net value [2] - The Morgan CSI Innovative Drug Industry ETF has a total scale of 34.9084 million CNY and has achieved a year-to-date return of 36.18%, ranking 1270 out of 4220 in its category [2] - The fund manager, Mao Shichao, has been in charge for 5 years and 140 days, with the best fund return during his tenure being 56.22% and the worst being -24.75% [3]
泰格医药涨超6% 公司海外临床运营业务呈现较快增长趋势 持续数字化及智能化投入
Zhi Tong Cai Jing· 2025-09-24 02:24
Group 1 - The stock price of Tigermed (300347)(03347) increased by over 6%, reaching 47.98 HKD with a trading volume of 62.54 million HKD [1] - Citic Securities reported that Tigermed is enhancing its global presence and service capabilities, with significant teams in regions such as the US, Europe, Middle East, Africa, Japan, and South Korea [1] - In the first half of the year, the company's domestic main business revenue was 1.638 billion CNY, a decrease of 10.1% year-on-year, while overseas main business revenue was 1.541 billion CNY, an increase of 4.6% year-on-year [1] Group 2 - The growth in overseas revenue is attributed to the company's continued global expansion and service capabilities, accelerating its internationalization process [1] - The overseas clinical business maintained rapid growth, with an increase in revenue from clinical trial technical services [1] - The company announced the acquisition of Japanese CRO Micron in July 2025, which will enhance its local team in Japan and expand its client coverage in the Asia-Pacific region [1] Group 3 - The overseas clinical operations business showed a rapid growth trend, particularly in North America, with significant new order contributions expected in the second half of the year [2] - The clinical registration business experienced a notable recovery, with revenue growth exceeding 20% year-on-year, driven by increased demand for IND-related services both domestically and internationally [2] - The company established a data governance team in the first half of the year, launching multiple digital products to enhance digital management and integrating AI technology to improve digital capabilities [2]
港股异动 | 泰格医药(03347)涨超6% 公司海外临床运营业务呈现较快增长趋势 持续数字化及智能化投入
智通财经网· 2025-09-24 02:23
Core Viewpoint - Tiger Med (03347) has seen a stock price increase of over 6%, attributed to its ongoing global expansion and service capabilities, particularly in overseas markets [1][2] Group 1: Financial Performance - In the first half of the year, the company's domestic main business revenue was 1.638 billion yuan, a year-on-year decrease of 10.1% [1] - The overseas main business revenue reached 1.541 billion yuan, showing a year-on-year growth of 4.6%, driven by the deepening of global layout and service capabilities [1] - The clinical registration business experienced a significant recovery, with revenue growth exceeding 20% year-on-year, benefiting from increased demand both domestically and internationally [2] Group 2: Strategic Initiatives - The company announced the acquisition of Japanese CRO Micron in July 2025, which will enhance its local team and expand client coverage in Japan and the Asia-Pacific region [1] - The establishment of a data governance team and the launch of multiple digital products have been initiated to improve digital management and integrate AI technology for enhanced operational efficiency [2] Group 3: Market Outlook - The overseas clinical operations business is showing a rapid growth trend, particularly in North America, with expectations of significant new order contributions in the second half of the year [2]
易方达基金减持泰格医药87.69万股 每股作价约46.57港元
Zhi Tong Cai Jing· 2025-09-22 11:57
香港联交所最新资料显示,9月17日,易方达基金减持泰格医药(03347)87.69万股,每股作价46.5701港 元,总金额约为4083.73万港元。减持后最新持股数目为1082.74万股,持股比例为8.79%。 ...
易方达基金减持泰格医药(03347)87.69万股 每股作价约46.57港元


智通财经网· 2025-09-22 11:54
智通财经APP获悉,香港联交所最新资料显示,9月17日,易方达基金减持泰格医药(03347)87.69万股, 每股作价46.5701港元,总金额约为4083.73万港元。减持后最新持股数目为1082.74万股,持股比例为 8.79%。 ...
9月17日生物经济(970038)指数跌0.55%,成份股药石科技(300725)领跌
Sou Hu Cai Jing· 2025-09-17 10:48
Group 1 - The Biotech Index (970038) closed at 2403.29 points, down 0.55%, with a trading volume of 25.269 billion yuan and a turnover rate of 1.59% [1] - Among the index constituents, 11 stocks rose, led by Jingxin Pharmaceutical with a 2.67% increase, while 38 stocks fell, with Yaoshi Technology leading the decline at 5.11% [1] - The top ten constituents of the Biotech Index include major companies such as Mindray Medical, with a weight of 13.82% and a market cap of 290.246 billion yuan, and other notable firms like Tigermed and Changchun High-tech [1] Group 2 - The net outflow of main funds from the Biotech Index constituents totaled 1.789 billion yuan, while retail investors saw a net inflow of 1.354 billion yuan [3] - Specific stocks like Boteng Co. experienced a net inflow of 73.5819 million yuan from main funds, while others like Jiayin Pharmaceutical saw a net outflow of 4.8669 million yuan [3] - The overall trend indicates a mixed sentiment among institutional and retail investors, with significant movements in individual stocks reflecting varying levels of confidence [3]
港股异动|泰格医药跌逾5% 遭易方达基金减持417.44万股
Ge Long Hui· 2025-09-17 07:39
| 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 費出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | | --- | --- | --- | --- | --- | --- | --- | | | 플 | 原因 | 股份數目 | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 福 | | | | | | | | 份自分比 | | | | | | | | ( % ) | | CS20250916E00196 | 4,174,400(L) 易方达基金管理有限公司 | 1201(L) | | HKD 44.3362 | 12,370,300(L) | 10.05(L) 11/09/2025 | 泰格医药(3347.HK)现跌5.13%报46.2港元,暂成交2.3亿港元,最新市值397.8亿港元。联交所最新权益披露资料显示,泰格医药于9月11日遭易方达基金管理 有限公司在场内以每股均价44.3362港元减持417.44万股,涉资约1.85亿港元。减持后,其持股比例由13.44%下降至10.05%。(格隆汇) ...
泰格医药(03347.HK)遭易方达基金减持417.44万股
Ge Long Hui· 2025-09-16 23:48
| 股份代號: | 03347 | | --- | --- | | 上市法國名稱: | 杭州泰格醫藥科技股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 17/08/2025 - 17/09/2025 | 格隆汇9月17日丨根据联交所最新权益披露资料显示,2025年9月11日,泰格医药(03347.HK)遭易方达基金管理有限公司在场内以每股均价44.3362港元减持 417.44万股,涉资约1.85亿港元。 减持后,易方达基金管理有限公司最新持股数目为1237.03万股,持股比例由13.44%下降至10.05%。 | 張格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | | 持有權益的股份數目 佔已發行的 有關事件的日期 相 | | | --- | --- | --- | --- | --- | --- | --- | --- | | | निर्म | 原因 | 股份數目 | | | (請參閱上述*註 | 有投票權股 (日 / 月 / 年) 福 | | | | | | | | | 份自分比 | | | | | | | | | (%) ...
易方达基金减持泰格医药417.44万股 每股作价约44.34港元


Zhi Tong Cai Jing· 2025-09-16 11:14
香港联交所最新资料显示,9月11日,易方达基金减持泰格医药(03347)417.44万股,每股作价44.3362港 元,总金额约为1.85亿港元。减持后最新持股数目为1237.03万股,持股比例为10.05%。 ...